A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer

Angiogenesis plays a key role in tumor development and αvβ3 integrin are overexpressed on the endothelial cell surface of newly forming vessels. 18F-Alfatide has favorable properties for αvβ3 integrin targeting and showed potential for imaging angiogenesis with Positron Emission Tomography (PET)/computed tomography (CT). In this study, 13 patients with non-small cell lung cancer (NSCLC) who underwent 18F-Alfatide PET/CT before surgery were enrolled. The uptake of all dissected lymph nodes (LNs) of 18F-Alfatide were assessed visually and analyzed with a maximum and mean standard uptake value (SUVmax, SUVmean) and SUV ratios. LN metastases were pathologically confirmed and 20 of 196 LNs were malignant. All malignant LNs were successfully visualized on 18F-Alfatide PET/CT in patients and the sensitivity, specificity and accuracy was 100.0%, 94.9% and 95.4%, respectively. SUVmax, SUVmean and SUV ratios in malignant LNs were significantly higher than in benign LNs for NSCLC patients (P < 0.001). The same result was observed in patients with adenocarcinoma and squamous cell carcinoma (P < 0.001). The 18F-Alfatide parameter shows high sensitivity (83.9–100%), specificity (78.6–96.7%) and accuracy (81.7–96.9%) according to thresholds calculated from receiver operating characteristic curve. Our results suggest that 18F-Alfatide PET/CT is valuable in the diagnosis of metastatic LNs for NSCLC patients.

[1]  B. Borisch,et al.  Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. , 2001, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[2]  L. Sancey,et al.  Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model. , 2008, Cancer biotherapy & radiopharmaceuticals.

[3]  Shuang Liu.  Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. , 2009, Bioconjugate chemistry.

[4]  D. Ruiter,et al.  Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. , 1997, International journal of cancer.

[5]  Xiaoyuan Chen,et al.  68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αvβ3 expression , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Ido D. Weiss,et al.  MicroPET Imaging of Integrin αvβ3 Expressing Tumors Using 89Zr-RGD Peptides , 2010, Molecular Imaging and Biology.

[7]  Rhona A. Berganos,et al.  Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. , 2011, Radiology.

[8]  A. Woodard,et al.  Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. , 1999, Cancer research.

[9]  C. Kim,et al.  Dual-time-point FDG PET/CT: Is It Useful for Lymph Node Staging in Patients with Non-Small-Cell Lung Cancer? , 2012, Nuclear Medicine and Molecular Imaging.

[10]  Xiaoyuan Chen,et al.  68Ga-labeled multimeric RGD peptides for microPET imaging of integrin {alpha}v{beta}3 expression , 2008 .

[11]  Young Joo Kim,et al.  Preparation of a Promising Angiogenesis PET Imaging Agent: 68Ga-Labeled c(RGDyK)–Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice , 2008, Journal of Nuclear Medicine.

[12]  Sibylle Ziegler,et al.  Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .

[13]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[14]  Horst Kessler,et al.  Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.

[15]  Ryan Park,et al.  MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[16]  E. Hostetler,et al.  Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 Determined from Whole-Body PET/CT in Monkeys and Humans , 2012, The Journal of Nuclear Medicine.

[17]  Han Wu,et al.  Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non–small‐cell lung cancer patients , 2013, International journal of cancer.

[18]  Q. Xie,et al.  First Experience of 18F-Alfatide in Lung Cancer Patients Using a New Lyophilized Kit for Rapid Radiofluorination , 2013, The Journal of Nuclear Medicine.

[19]  A. Hui,et al.  The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide 18F-AH111585 in Healthy Volunteers , 2008, Journal of Nuclear Medicine.

[20]  Matthias Glaser,et al.  Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients , 2008, Journal of Nuclear Medicine.

[21]  Horst Kessler,et al.  Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man , 2006, Clinical Cancer Research.

[22]  Yong Song,et al.  Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer: A Bivariate Systematic Review and Meta-Analysis , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  T. Hara,et al.  Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  M. Schwaiger,et al.  Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  P. Dey,et al.  18F-FDG and 18F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes , 2016, Annals of Nuclear Medicine.

[26]  M. Wallace,et al.  Minimally invasive endoscopic staging of suspected lung cancer. , 2008, JAMA.

[27]  C. Mountain,et al.  Regional lymph node classification for lung cancer staging. , 1997, Chest.

[28]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  G. Wang,et al.  Biodistribution and clearance of 99mTc-labeled Arg-Gly-Asp (RGD) peptide in rats with ischemic acute renal failure. , 1996, Journal of the American Society of Nephrology : JASN.

[30]  Wei Zhang,et al.  68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer , 2015, The Journal of Nuclear Medicine.

[31]  Meng Li,et al.  Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells. , 2013, Oncology reports.

[32]  G. Mizejewski,et al.  Role of integrins in cancer: survey of expression patterns. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[33]  Rex Moats,et al.  18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. , 2004, Nuclear medicine and biology.

[34]  Jinming Yu,et al.  A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  J. Sengupta.  The Nonparametric Approach , 1989 .

[36]  Ulrich Keilholz,et al.  Immunohistochemical analysis of integrin αvβ3 expression on tumor‐associated vessels of human carcinomas , 1997 .

[37]  M. Schwaiger,et al.  Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. , 2001, Cancer research.

[38]  K. Ishiwata,et al.  A pilot study of 4′-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer , 2014, EJNMMI Research.

[39]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.